[
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For May 2025",
    "summary": "Dividend Aristocrats lag behind the S&P 500 in April, but 25 are undervalued with 10% returns potential. Click to read about promising Aristocrats.",
    "url": "https://finnhub.io/api/news?id=f464ee9b58092cefa3cc5defb8d523f2a517a541963eb0ee91228b354b0a2cd8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745957242,
      "headline": "Best Dividend Aristocrats For May 2025",
      "id": 134137634,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2168720864/image_2168720864.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats lag behind the S&P 500 in April, but 25 are undervalued with 10% returns potential. Click to read about promising Aristocrats.",
      "url": "https://finnhub.io/api/news?id=f464ee9b58092cefa3cc5defb8d523f2a517a541963eb0ee91228b354b0a2cd8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis",
    "summary": "AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation. Despite a 13% rise in its share price over the past week, AbbVie's gains were in line with the broader market's 7% climb, suggesting these product developments and positive sales growth added weight to the general upward momentum. Meanwhile, the broader market's reaction to strong earnings...",
    "url": "https://finnhub.io/api/news?id=8b5de97808063aaba3b0d083416dd2837b67d6ec7432eb0b6a8ece167e07d4f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745949610,
      "headline": "AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis",
      "id": 134141618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation. Despite a 13% rise in its share price over the past week, AbbVie's gains were in line with the broader market's 7% climb, suggesting these product developments and positive sales growth added weight to the general upward momentum. Meanwhile, the broader market's reaction to strong earnings...",
      "url": "https://finnhub.io/api/news?id=8b5de97808063aaba3b0d083416dd2837b67d6ec7432eb0b6a8ece167e07d4f6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=e83327c1a593833a3e163d874c8abe149d5a7238ccd012faf95bea0d350ac71a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745931615,
      "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 134130970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=e83327c1a593833a3e163d874c8abe149d5a7238ccd012faf95bea0d350ac71a"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=03d27904ab2d8f75ead48ab6dccac41528dde8e3ca5beda022374e37c97a39f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745931608,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 134130971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=03d27904ab2d8f75ead48ab6dccac41528dde8e3ca5beda022374e37c97a39f0"
    }
  },
  {
    "ts": null,
    "headline": "RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)",
    "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.",
    "url": "https://finnhub.io/api/news?id=644fed8bcc3aa5df149be768845a6700ca5a52e3160fa668bc2622c532e353d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745926200,
      "headline": "RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)",
      "id": 134130972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.",
      "url": "https://finnhub.io/api/news?id=644fed8bcc3aa5df149be768845a6700ca5a52e3160fa668bc2622c532e353d9"
    }
  },
  {
    "ts": null,
    "headline": "United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect",
    "summary": "Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=c012a059f3a7536f0f66dd3d34f5da45fdc73d7144e2e61f7695165de8129f13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745910653,
      "headline": "United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect",
      "id": 134130973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=c012a059f3a7536f0f66dd3d34f5da45fdc73d7144e2e61f7695165de8129f13"
    }
  },
  {
    "ts": null,
    "headline": "Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV",
    "summary": "NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=6ef7d62e27b90f101142716be60cac83031657f8b1edd576851447f57ffb8c83",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745905577,
      "headline": "Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV",
      "id": 134123463,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=6ef7d62e27b90f101142716be60cac83031657f8b1edd576851447f57ffb8c83"
    }
  }
]